Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akihisa Yabe is active.

Publication


Featured researches published by Akihisa Yabe.


Cardiovascular Drugs and Therapy | 2004

Nicorandil Protects Against Lethal Ischemic Ventricular Arrhythmias and Up-regulates Endothelial Nitric Oxide Synthase Expression and Sulfonylurea Receptor 2 mRNA in Conscious Rats with Acute Myocardial Infarction

Shigeo Horinaka; Naohiko Kobayashi; Akihisa Yabe; Hiroshi Asakawa; Hiroshi Yagi; Yousuke Mori; Yusuke Tsubokou; Koutarou Yoshida; Shigefumi Nakano; Hiroaki Matsuoka

Nicorandil is an adenosine triphosphate sensitive K (K-ATP) channel opener and a nitric oxide donor. K-ATP channels and nitric oxide are important factors in ischemic preconditioning, which in turn suppresses reperfusion arrhythmias. The present study sought to evaluate whether nicorandil suppresses ischemic-induced ventricular arrhythmias and enhances sulfonylurea receptors (SUR 2; subunit of K-ATP channel), endothelial nitric oxide (eNOS), and inducible nitric oxide (iNOS) expression in the left ventricle after myocardial infarction without reperfusion. Thirty male Sprague-Dawley rats at 7 weeks of age were separated into three groups, as follows. Acute myocardial infarction was induced in twenty rats by ligating the left main coronary artery. Ten of these twenty rats were continuously administered nicorandil at 3 mg/kg/day i.p. The other ten rats were left untreated. The ten controls were untreated and sham-operated. After coronary ligation, ventricular arrhythmias were evaluated from stored ECG signals. At 24 hours after treatment, eNOS, iNOS, and SUR2 mRNA levels and eNOS, iNOS expression in the left ventricle were determined by reverse transcription polymerase chain reaction (RT-PCR) and by immunohistochemical staining, respectively. Nicorandil suppressed the total number of ventricular arrhythmias from 1 to 2 hours, the total duration of ventricular tachycardia from 2 to 3 hours, and that of ventricular fibrillation from 1 to 2 and from 4 to 5 hours after coronary ligation. Nicorandil improved the survival rate 24 hours after coronary ligation. Levels of SUR2 mRNA increased only in left ventricles treated with nicorandil, particularly in the non-ischemic myocardium. eNOS mRNA was enhanced 2.2-fold in the area at risk in infarcted controls compared to sham-operated rats. In the non-ischemic area and area at risk of rats treated with nicorandil compared to sham-operated rats, eNOS mRNA was enhanced 3.3- and 2.7-fold, respectively. Staining indicated that the highest concentrations of eNOS occurred in the endothelium and myocardium of the non-ischemic area of rats treated with nicorandil. iNOS mRNA was present in both the area at risk and the non-ischemic area only in infarcted rats, and levels thereof were higher in the area at risk than in the non-ischemic area. However, there was no difference in iNOS mRNA levels between nicorandil-treated rats and controls. iNOS exhibited stronger staining in the area at risk than in the non-ischemic area of both nicorandil-treated and infarcted controls, with no differences between these two groups of rats. The mechanisms of protection against lethal ventricular tachyarrhythmia in nicorandil may increase nitric oxide release by upregulated eNOS expression through the opening of K-ATP channels and/or a K-ATP channels opener itself after acute myocardial infarction.


The American Journal of Medicine | 2004

Association of plasma atrial natriuretic peptide, n-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function

Toshio Nishikimi; Yosuke Mori; Kimihiko Ishimura; Kazuyoshi Tadokoro; Hiroshi Yagi; Akihisa Yabe; Shigeo Horinaka; Hiroaki Matsuoka


Clinical Science | 2001

Elevation of two molecular forms of adrenomedullin in plasma and urine in patients with acute myocardial infarction treated with early coronary angioplasty

Hiroshi Asakawa; Toshio Nishikimi; Takeshi Suzuki; Suomi Hara; Yusuke Tsubokou; Hiroshi Yagi; Akihisa Yabe; Noriaki Tsuchiya; Shigeo Horinaka; Kenji Kangawa; Hiroaki Matsuoka


Journal of Electrocardiology | 2001

Alternans of ventricular gradient during percutaneous transluminal coronary angioplasty

Shigeo Horinaka; Suomi Hara; Noriaki Tsuchiya; Akihisa Yabe; Hiroshi Asakawa; Hiroshi Yagi; Yousuke Mori; Hiroaki Matsuoka


Japanese Circulation Journal-english Edition | 2009

FRS-080 Effects of Nicorandil on Cardiovascular Events in Patients with Coronary Artery Disease from the Japanese Coronary Artery Disease (JCAD) Study(FRS17,Novel Approaches to Treatment of CAD (IHD),Featured Research Session (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

Shigeo Horinaka; Akihisa Yabe; Hiroshi Yagi; Hiroaki Matsuoka


Japanese Circulation Journal-english Edition | 2009

OJ-181 Oral Nicorandil Treatment after Acute Myocardial Infarction Improved Clinical Outcome in the Japanese Coronary Artery Disease (JCAD) Study(OJ31,ACS/AMI (Clinical/Treatment) (IHD),Oral Presentation (Japanese),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

Hiroshi Yagi; Shigeo Horinaka; Akihisa Yabe; Hitoshi Hara; Hiroaki Matsuoka


Japanese Circulation Journal-english Edition | 2008

PE-288 High-sensitivity C-reactive Protein Could Reflect Coronary Atherosclerosis in the Ischemic Heart Disease(Chronic coronary heart disease/Remodeling(02)(IHD),Poster Session(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Tomomi Iemura; Shigeo Horinaka; Hitoshi Hara; Hiroshi Yagi; Kotaro Yoshida; Akihisa Yabe; Hiroaki Matsuoka


Japanese Circulation Journal-english Edition | 2008

PE-380 Cardio Ankle Vascular Index (CAVI) is Useful Index for Evaluating Coronary Risk(Atherosclerosis, clinical(07)(IHD),Poster Session(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Shigeo Horinaka; Hiroaki Yagi; Hitoshi Hara; Tomomi Iemura; Kotaro Yoshida; Akihisa Yabe; Hiroaki Matsuoka


Japanese Circulation Journal-english Edition | 2008

PE-279 Carvedilol in Idophasic Dilated Cardiomyopathy : is It Possible to Identify Factors Predictive of Improvement of LVEF?(Cardiomyopathy, basic/clinical(04)(M),Poster Session(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Hitoshi Hara; Shigeo Horinaka; Tomomi Iemura; Kimihiko Ishimura; Kotaro Yoshida; Hiroshi Yagi; Akihisa Yabe; Hiroaki Matsuoka


Japanese Circulation Journal-english Edition | 2007

OE-171 Olmesartan Medoxomil Stabilizes Vascular Inframmation and Improves Vascular Stiffness(Hypertension, clinical-02, The 71st Annual Scientific Meeting of the Japanese Circulation Society)

Shigeo Horinaka; Akihisa Yabe; Hiroshi Yagi; Hitoshi Hara; Hiroaki Matsuoka

Collaboration


Dive into the Akihisa Yabe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge